At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 22, 2026 at 07:00 ET
TScan Therapeutics presented positive Phase 1 Cohort C data for TSC-101, showing 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first infusion, with all 5 patients assessed after a second infusion also achieving complete chimerism. The company remains on track to enroll the first patient in the pivotal Phase 3 ALLOHA-2 study this month, supporting a bullish catalyst for this clinical-stage biotech.
- 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion
- All 5 patients assessed after second infusion achieved complete chimerism
- 93% of patients responded with decreasing recipient chimerism in higher-risk population vs Cohort A and control
- One TP53-mutated AML patient remained in complete donor chimerism 6 months post-HCT
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access